Key result
Renalase protects organs from ischemic injury via PMCA4b, whereas its inhibition slows tumor growth.
Why the study?
A paradigm shift in understanding the cellular actions of renalase reveals that it functions as a cytoprotective cytokine via receptor-mediated signalling rather than solely as an oxidase, while dysregulated signalling may also sustain cancer cell growth.
Answers are grounded in this paper and cite their sources.
Renalase modulation may balance organ protection against tumor risk; leaves open selective PMCA4b targeting pending prospective trials.
Renalase was discovered as a protein synthesized by the kidney and secreted in blood where it circulates at a concentration of approximately 3-5 μg/ml. Initial reports suggested that it functioned as an NAD(P)H oxidase and could oxidize catecholamines. Administration of renalase lowers blood pressure and heart rate and also protects cells and organs against ischaemic and toxic injury. Although renalase's protective effect was initially ascribed to its oxidase properties, a paradigm shift in our understanding of the cellular actions of renalase is underway. We now understand that, independent of its enzymatic properties, renalase functions as a cytokine that provides protection to cells, tissues and organs by interacting with its receptor to activate protein kinase B, JAK/STAT, and the mitogen-activated protein kinase pathways. In addition, recent studies suggest that dysregulated renalase signalling may promote survival of several tumour cells due to its capacity to augment expression of growth-related genes. In this review, we focus on the cytoprotective actions of renalase and its capacity to sustain cancer cell growth and also the translational opportunities these findings represent for the development of novel therapeutic strategies for organ injury and cancer.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2017) conducted a review in Acute organ injury (renal, cardiac, pancreatic) and cancer (pancreatic ductal adenocarcinoma, melanoma). Extracellular renalase / anti-renalase antibodies was evaluated. Extracellular renalase protects organs against ischemic and toxic injury via PMCA4b receptor-mediated survival signaling, while its inhibition suppresses tumor growth in pancreatic cancer and melanoma.
Synapse has enriched 10 related papers. Consider them for comparative context: